$4.5
Revenue is up for the last 4 quarters, 10.2M → 14.47M (in $), with an average increase of 11.0% per quarter
Netprofit is up for the last 4 quarters, -12.69M → -10.37M (in $), with an average increase of 7.0% per quarter
In the last 1 year, Boston Scientific Corp. has given 23.9% return, outperforming this stock by 51.7%
3.33%
Downside
Day's Volatility :3.87%
Upside
0.55%
72.89%
Downside
52 Weeks Volatility :81.23%
Upside
30.77%
Period | NEUROPACE INC | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -12.28% | 0.3% | -6.7% |
6 Months | 179.5% | -6.1% | -3.7% |
1 Year | -27.77% | -4.8% | -6.3% |
3 Years | -81.97% | 23.8% | 26.9% |
Market Capitalization | 114.3M |
Book Value | $1.08 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.85 |
Wall Street Target Price | 6.9 |
Profit Margin | -94.61% |
Operating Margin TTM | -80.94% |
Return On Assets TTM | -20.91% |
Return On Equity TTM | -101.86% |
Revenue TTM | 48.6M |
Revenue Per Share TTM | 1.96 |
Quarterly Revenue Growth YOY | 27.200000000000003% |
Gross Profit TTM | 32.5M |
EBITDA | -39.1M |
Diluted Eps TTM | -1.85 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.81 |
EPS Estimate Next Year | -1.63 |
EPS Estimate Current Quarter | -0.46 |
EPS Estimate Next Quarter | -0.47 |
What analysts predicted
Upside of 53.33%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 37.0M | - |
Net Income | -30.0M | - |
Net Profit Margin | -81.07% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 41.1M | ↑ 11.27% |
Net Income | -24.3M | ↓ 19.0% |
Net Profit Margin | -59.02% | ↑ 22.05% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 45.2M | ↑ 9.83% |
Net Income | -36.1M | ↑ 48.61% |
Net Profit Margin | -79.85% | ↓ 20.83% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 45.5M | ↑ 0.75% |
Net Income | -47.1M | ↑ 30.49% |
Net Profit Margin | -103.43% | ↓ 23.58% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 11.0M | ↑ 6.36% |
Net Income | -36.1M | ↑ 346.37% |
Net Profit Margin | -328.09% | ↓ 249.91% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 11.4M | ↑ 3.43% |
Net Income | -11.5M | ↓ 68.23% |
Net Profit Margin | -100.76% | ↑ 227.33% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 10.2M | ↓ 10.32% |
Net Income | -12.7M | ↑ 10.72% |
Net Profit Margin | -124.41% | ↓ 23.65% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 11.2M | ↑ 9.38% |
Net Income | -11.8M | ↓ 7.13% |
Net Profit Margin | -105.63% | ↑ 18.78% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 12.8M | ↑ 14.63% |
Net Income | -11.1M | ↓ 5.42% |
Net Profit Margin | -87.15% | ↑ 18.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.5M | ↑ 13.16% |
Net Income | -10.4M | ↓ 6.92% |
Net Profit Margin | -71.69% | ↑ 15.46% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 21.1M | - |
Total Liabilities | 150.4M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 56.0M | ↑ 165.23% |
Total Liabilities | 203.8M | ↑ 35.45% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 133.6M | ↑ 138.72% |
Total Liabilities | 60.1M | ↓ 70.53% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 114.1M | ↓ 14.57% |
Total Liabilities | 79.3M | ↑ 32.09% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 133.6M | ↓ 5.45% |
Total Liabilities | 60.1M | ↑ 0.86% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 129.0M | ↓ 3.43% |
Total Liabilities | 66.2M | ↑ 10.16% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 118.5M | ↓ 8.09% |
Total Liabilities | 65.6M | ↓ 0.78% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 120.5M | ↑ 1.63% |
Total Liabilities | 77.1M | ↑ 17.4% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 114.1M | ↓ 5.29% |
Total Liabilities | 79.3M | ↑ 2.94% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 106.3M | ↓ 6.87% |
Total Liabilities | 78.8M | ↓ 0.69% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.0M | - |
Investing Cash Flow | 3.6M | - |
Financing Cash Flow | 21.4M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.6M | ↓ 13.65% |
Investing Cash Flow | -10.8M | ↓ 397.6% |
Financing Cash Flow | 55.0M | ↑ 157.41% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -24.6M | ↑ 13.74% |
Investing Cash Flow | -85.4M | ↑ 693.13% |
Financing Cash Flow | 102.5M | ↑ 86.38% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -36.0 | ↓ 100.0% |
Investing Cash Flow | 23.8M | ↓ 127.87% |
Financing Cash Flow | 0.0 | ↓ 100.0% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.2M | ↑ 85.42% |
Investing Cash Flow | -154.0K | ↓ 18.95% |
Financing Cash Flow | 911.0K | ↑ 0.0% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -11.4M | ↑ 38.89% |
Investing Cash Flow | -306.0K | ↑ 98.7% |
Financing Cash Flow | 1000.0 | ↓ 99.89% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.7M | ↓ 6.45% |
Investing Cash Flow | 8.2M | ↓ 2791.5% |
Financing Cash Flow | 635.0K | ↑ 63400.0% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.0M | ↓ 34.56% |
Investing Cash Flow | 7.0M | ↓ 15.38% |
Financing Cash Flow | -8.0K | ↓ 101.26% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.7M | ↓ 133.41% |
Investing Cash Flow | 10.1M | - |
Financing Cash Flow | -255.0K | ↓ 59.39% |
Sell
Neutral
Buy
NEUROPACE INC is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() NEUROPACE INC | -8.16% | 179.5% | -27.77% | -81.97% | -81.97% |
![]() Stryker Corporation | -9.11% | 19.97% | 16.24% | 39.26% | 58.16% |
![]() Boston Scientific Corp. | -3.3% | 14.74% | 24.51% | 34.4% | 69.07% |
![]() Edwards Lifesciences Corp. | -6.33% | 9.57% | -18.68% | 9.48% | 81.0% |
![]() Abbott Laboratories | -7.42% | -2.03% | -12.42% | 8.38% | 67.81% |
![]() Medtronic PLC | -10.17% | 6.51% | -18.66% | -17.37% | -4.6% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() NEUROPACE INC | NA | NA | NA | -1.81 | -1.02 | -0.21 | 0.0 | 1.08 |
![]() Stryker Corporation | 39.65 | 39.65 | 2.85 | 10.16 | 0.16 | 0.06 | 0.01 | 44.51 |
![]() Boston Scientific Corp. | 91.11 | 91.11 | 2.53 | 1.95 | 0.05 | 0.04 | 0.0 | 12.42 |
![]() Edwards Lifesciences Corp. | 35.05 | 35.05 | 3.07 | 2.55 | 0.25 | 0.13 | 0.0 | 9.87 |
![]() Abbott Laboratories | 24.81 | 24.81 | 18.76 | 4.4 | 16.03 | 0.06 | 0.02 | 21.28 |
![]() Medtronic PLC | 18.2 | 18.2 | 3.04 | 5.28 | 7.81 | 0.04 | 0.03 | 38.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() NEUROPACE INC | Buy | $114.3M | -81.97% | NA | -94.61% |
![]() Stryker Corporation | Buy | $103.4B | 58.16% | 39.65 | 13.86% |
![]() Boston Scientific Corp. | Buy | $74.7B | 69.07% | 91.11 | 6.92% |
![]() Edwards Lifesciences Corp. | Buy | $49.7B | 81.0% | 35.05 | 27.07% |
![]() Abbott Laboratories | Buy | $177.6B | 67.81% | 24.81 | 13.98% |
![]() Medtronic PLC | Buy | $111.1B | -4.6% | 18.2 | 13.21% |
KCK Ltd
Orbimed Advisors, LLC
Soleus Capital Management, L.P.
Morgan Stanley - Brokerage Accounts
FMR Inc
Millennium Management LLC
NEUROPACE INC’s price-to-earnings ratio stands at None
Read MoreBased in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy, and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Organization | NEUROPACE INC |
Employees | 163 |
CEO | Mr. Michael L. Favet |
Industry | Healthcare |
Presto Automation Inc
$3.59
+63.93%
D-MARKET ELECTRONIC SERVICES
$1.04
+4.0%
Mexico MSCI Capped ETF iShares
$61.22
+2.03%
Global X S&P Catholic Values Developed ex-US ETF
$27.84
+0.0%
IndexIQ ETF Trust - IQ Chaikin U.S. Small Cap ETF
$30.75
+0.5%
DFA Dimensional Internatl High Profitability ETF
$24.08
+1.09%
Precigen Inc
$1.22
+1.67%
EXSCIENTIA PLC
$7.96
+1.14%
FIRST TRUST NASDAQ ARTIFICIA
$43.68
+2.68%